Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies-Reference-Cited by-同舟云学术

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Published:2022-10-26 Issue:5 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Xu Congjuan¹,Wei Xiaoya¹,Jin Yongxin¹^ORCID,Bai Fang¹^ORCID,Cheng Zhihui¹,Chen Shuiping²,Pan Xiaolei¹^ORCID,Wu Weihui¹^ORCID

Affiliation:

1. State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, Tianjin, China

2. Department of Laboratory Medicine, 5th Medical Center of PLA General Hospital, Beijing, China

Abstract

The increasing bacterial antibiotic resistance is a serious threat to global public health, which demands novel antimicrobial medicines and treatment strategies. Eravacycline is a newly approved antibiotic that belongs to the tetracycline antibiotics.

Funder

MOE | Fundamental Research Funds for the Central Universities

Tianjin Graduate Scientific Research Innovation Project

MOST | National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01390-22

Reference62 articles.